MAX Chat
Company Analysis Arcutis Biotherapeutics
1. Summary
Advantages
- Price (17.29 $) is less than fair price (17.53 $)
- The stock's return over the last year (15.81%) is higher than the sector average (-11.01%).
Disadvantages
- Dividends (0%) are below the sector average (1.35%).
- Current debt level 31.7% has increased over 5 years from 0.2869%.
- The company's current efficiency (ROE=-113.76%) is lower than the sector average (ROE=-70.06%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Arcutis Biotherapeutics | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0.2% | -1.1% | 0.8% |
| 90 days | 13.2% | -0.1% | 11% |
| 1 year | 15.8% | -11% | 16.1% |
ARQT vs Sector: Arcutis Biotherapeutics has outperformed the "Healthcare" sector by 26.81% over the past year.
ARQT vs Market: Arcutis Biotherapeutics has underperformed the market marginally by -0.255% over the past year.
Stable price: ARQT is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ARQT with weekly volatility of 0.304% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (17.29 $) is lower than the fair price (17.53 $).
Price not significantly lower than the fair price: The current price (17.29 $) is slightly lower than the fair price by 1.4%.
4.2. P/E
P/E vs Sector: The company's P/E (-13.5) is lower than that of the sector as a whole (27.8).
P/E vs Market: The company's P/E (-13.5) is lower than that of the market as a whole (51.19).
4.3. P/BV
P/BV vs Sector: The company's P/BV (10.7) is higher than that of the sector as a whole (10.5).
P/BV vs Market: The company's P/BV (10.7) is lower than that of the market as a whole (18.13).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (8.57) is higher than that of the sector as a whole (4.08).
P/S vs Market: The company's P/S indicator (8.57) is lower than that of the market as a whole (27.99).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-15.73) is lower than that of the sector as a whole (18.1).
EV/Ebitda vs Market: The company's EV/Ebitda (-15.73) is lower than that of the market as a whole (36.56).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 0.6428% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0.6428%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (1364.84%).
5.4. ROE
ROE vs Sector: The company's ROE (-113.76%) is lower than that of the sector as a whole (-70.06%).
ROE vs Market: The company's ROE (-113.76%) is lower than that of the market as a whole (34.77%).
5.5. ROA
ROA vs Sector: The company's ROA (-40.58%) is lower than that of the sector as a whole (8.48%).
ROA vs Market: The company's ROA (-40.58%) is lower than that of the market as a whole (11.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.03%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.35%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
